Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
US11471478B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Sep 28, 2018 |
| Grant date | Oct 18, 2022 |
| Priority date | — |
| Expiry date | Sep 28, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In some embodiments, the present disclosure provides certain compositions and methods that may be useful in the treatment and/or prevention of malignant, neurodegenerative, vascular, metabolic, inflammatory, autoimmune, pulmonary, fibrotic, hepatic, lysosomal storage, or viral disease, disorder, or condition, such as carcinomas, Alzheimer's and Parkinson's disease, multiple sclerosis, Paget's disease, or other aspects of aging, such as atherosclerosis or type-2 diabetes. In some such embodiments, compositions are provided that contain at least one cyclodextrin active agent, such as alpha-cyclodextrin, or an analogue or derivative thereof. In some embodiments, the composition is a clathrate of hydroxypropyl-alpha-cyclodextrin and sodium caprate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.